{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:30:56Z","timestamp":1787776256966,"version":"build-2784847793"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Off-label drug use (OLDU) refers to the prescription of a currently available and marketed medication for a use that has never been approved by the Food and Drug Administration (FDA). Misoprostol is one of the drugs which is used off-label. This drug, authorized for the treatment or prevention of peptic ulcers and other stomach disorders, is commonly used off-label for inducing labor or intrauterine device insertion. This research focuses on identifying the percentage of morbidity and mortality by off-label use of misoprostol; classifying the most common off-label misoprostol use in Tabuk hospitals; and determining the availability of policy and procedures behind prescribing the off-label misoprostol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Retrospective observational study was carried out. Data were collected from patients\u2019 files for those admitted to the maternity wards in Tabuk Hospitals from March 2019 until September 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Approximately 53% of cases were diagnosed with missed abortion. The mean time for abortion after administering misoprostol was 20.7 \u00b1 28.2h. About 76% of women had an indication of bleeding. Guidelines were not followed with respect to dosage regimen. The mean of hospital stay was 3 days. There were no significant complications associated with the administration of misoprostol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>There is no policy and procedure available in the hospital regarding off-label use of misoprostol. Moreover, physicians have low adherence to the guideline in terms of dosage, interval, and route of administration for each indication in obstetrics and gynecology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jpbs.jpbs_368_20","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T11:29:46Z","timestamp":1613993386000},"page":"88-92","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Retrospective Study on the Pattern of Off-label Use of Misoprostol in Tabuk, Saudi Arabia"],"prefix":"10.4103","volume":"13","author":[{"given":"Nouf M.","family":"Alharthi","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohannad Sahaw","family":"Alsaeed","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Omar","family":"Alsharif","sequence":"additional","affiliation":[{"name":"Director of Pharmaceutical Care Administration in Tabuk Region, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Ghabbash","family":"Almalki","sequence":"additional","affiliation":[{"name":"Board Certified Pharmacotherapy Specialist, Pharmacy Director and Head of DIC, Umluj General Hospital, Tabuk, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael Saeed","family":"Alshehri","sequence":"additional","affiliation":[{"name":"King Khalid Hospital, Tabuk, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousalya","family":"Prabahar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"R1-20250523","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1056\/NEJMp0802107","article-title":"Regulating off-label drug use\u2013rethinking the role of the FDA","volume":"358","author":"Stafford","year":"2008","journal-title":"N Engl J Med"},{"key":"R3-20250523","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4172\/2161-0495.1000120","article-title":"Pharmaceutical production problems detected by adverse drug reactions reports: a documentary study from the German Democratic Republic, 1982 to 1990","volume":"2","author":"Aagaard","year":"2012","journal-title":"J Clinic Toxicol"},{"key":"R4-20250523","first-page":"122","article-title":"Position and processing of adverse drug reactions directly submitted by patients to National Regulatory Authorities in Europe","volume":"2","author":"Srba","year":"2014","journal-title":"J Pharmacovigilance"},{"key":"R5-20250523","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s11096-011-9569-z","article-title":"Perceptions and attitudes of Jordanian paediatricians towards off-label paediatric prescribing","volume":"33","author":"Mukattash","year":"2011","journal-title":"Int J Clin Pharm"},{"key":"R6-20250523","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.gyobfe.2015.04.010","article-title":"[Off-label drug use of the misoprostol in gynecology & obstetrics: from a medico-economics benefit to a potential legal risk]","volume":"43","author":"Decamps-Mini","year":"2015","journal-title":"Gynecol Obstet Fertil"},{"key":"R8-20250523","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejogrb.2014.11.026","article-title":"Off-label use of misoprostol for labor induction in Germany: a national survey","volume":"187","author":"Voigt","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R10-20250523","doi-asserted-by":"crossref","first-page":"eAO5029","DOI":"10.31744\/einstein_journal\/2020AO5029","article-title":"Use of misoprostol in the treatment of postpartum hemorrhage: a pharmacoepidemiological approach","volume":"18","author":"Koch","year":"2020","journal-title":"Einstein (Sao Paulo)"},{"key":"R11-20250523","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41598-017-01892-0","article-title":"Misoprostol for medical treatment of missed abortion: a systematic review and network meta-analysis","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"R12-20250523","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4103\/0253-7613.77356","article-title":"Comparison of sublingual, vaginal, and oral misoprostol in cervical ripening for first trimester abortion","volume":"43","author":"Parveen","year":"2011","journal-title":"Indian J Pharmacol"},{"key":"R13-20250523","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1067\/S0002-9378(03)00659-8","article-title":"A randomized comparison of two regimens of misoprostol for second-trimester pregnancy termination","volume":"189","author":"Feldman","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R14-20250523","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/01.AOG.0000206737.68709.3e","article-title":"Factors related to successful misoprostol treatment for early pregnancy failure","volume":"107","author":"Creinin","year":"2006","journal-title":"Obstet Gynecol"},{"key":"R15-20250523","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/13625180500178676","article-title":"First-trimester pregnancy termination with 800 microg of vaginal misoprostol every 12h","volume":"10","author":"Salakos","year":"2005","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"R16-20250523","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/AOG.0000000000003017","article-title":"Efficacy of misoprostol alone for first-trimester medical abortion: a systematic review","volume":"133","author":"Raymond","year":"2019","journal-title":"Obstet Gynecol"}],"container-title":["Journal of Pharmacy and Bioallied Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.JPBS_368_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:04:21Z","timestamp":1787774661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.JPBS_368_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jpbs.jpbs_368_20","relation":{},"ISSN":["0976-4879","0975-7406"],"issn-type":[{"value":"0976-4879","type":"print"},{"value":"0975-7406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,16]]},"assertion":[{"value":"2020-06-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}